Bristol-Myers hep C trial hits the skids on safety concerns

In January, Bristol-Myers Squibb ($BMY) paid $2.5 billion for Inhibitex, jazzed by the prospects for its hepatitis C drug candidate. Now, 7 months later, that drug is in deep trouble. The company stopped dosing in a Phase IIb trial after one patient developed heart failure. Report